AKT1 and prostate carcinoma: We found that P-ERK was significantly reduced after knocking down IRS-1 in DU145 and PC-3 cells, while there was little change in P-AKT (Fig. 5a, b), suggesting that IRS-1 mainly activates the ERK signaling pathway in prostate cancer.